LENZ vs. HCM, MIRM, VCEL, BHC, BHVN, TARS, GMTX, AAPG, BLTE, and NAMS
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), Vericel (VCEL), Bausch Health Companies (BHC), Biohaven (BHVN), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.
LENZ Therapeutics vs.
LENZ Therapeutics (NASDAQ:LENZ) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
HUTCHMED's return on equity of 0.00% beat LENZ Therapeutics' return on equity.
LENZ Therapeutics currently has a consensus target price of $46.60, suggesting a potential upside of 95.63%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 38.08%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe LENZ Therapeutics is more favorable than HUTCHMED.
In the previous week, LENZ Therapeutics had 10 more articles in the media than HUTCHMED. MarketBeat recorded 14 mentions for LENZ Therapeutics and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.66 beat LENZ Therapeutics' score of 0.33 indicating that HUTCHMED is being referred to more favorably in the news media.
HUTCHMED has higher revenue and earnings than LENZ Therapeutics.
HUTCHMED received 302 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 66.39% of users gave HUTCHMED an outperform vote.
LENZ Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
LENZ Therapeutics beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 4/18/2025 by MarketBeat.com Staff
